9 terminated. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Terminated 9 |
| Phase 2 | 1 | Terminated 1 |
Follow Child Development Disorders, Pervasive: new trials by email Literature Review of Child Development Disorders, Pervasive trials Research Report on Child Development Disorders, Pervasive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Amitriptyline for Repetitive Behaviors in Autism Spectrum Disorders amitriptyline - Autism Spectrum Disorder, Repetitive Compulsive Behavior | Phase 3 | Terminated | University of Missouri, Kansas City | 1 | 2023-11-01 | 2025-05-30 |
| Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions Memantine Hydrochloride, Placebo - Autism, Autism Spectrum Disorder | Phase 3 | Terminated | Massachusetts General Hospital | 25 | 2018-11-13 | 2026-02-25 |
| Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder. BUMETANIDE (S95008) for week 0 - 26, PLACEBO for week 0 - 26, Open-Label BUMETANIDE (S95008) for weeks 26 - 52 - Autism Spectrum Disorder (ASD) | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 211 | 2018-10-04 | 2023-06-05 |
| Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder Bumetanide Oral Solution, Placebo - Autism Spectrum Disorder (ASD) | Phase 3 | Terminated | Institut de Recherches Internationales Servier | 211 | 2018-09-24 | 2024-07-25 |
| A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension Balovaptan, Placebo - Autism Spectrum Disorder | Phase 3 | Terminated | Hoffmann-La Roche | 322 | 2018-08-08 | 2021-10-27 |
| Oxytocin in Adolescents With Autism Spectrum Disorders OCYTOCINA - SPRAY NASAL - Autism Spectrum Disorder | Phase 2 / Phase 3 | Terminated | University of Sao Paulo General Hospital | 30 | 2015-06-01 | 2019-10-28 |
| Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders STX209 (arbaclofen) - Autism Spectrum Disorders | Phase 3 | Terminated | Seaside Therapeutics, Inc. | 165 | 2011-11-01 | 2013-07-31 |
| Extended Management and Measurement of Autism Fluoxetine (prozac) - Autistic Disorder | Phase 3 | Terminated | Neuropharm | 128 | 2008-11-01 | 2010-02-23 |
| Synthetic Human Secretin in Children With Autism and Gastrointestinal Dysfunction RG1068 (Synthetic Human Secretin) - Autism | Phase 3 | Terminated | Repligen Corporation | 2002-04-01 | 2005-11-21 |
Autism Spectrum Disorder (7) · Autistic Disorder (6) · Social Skills (1) · non-verbal learning disabilities (1)
Mental Disorders (9) · Neurodevelopmental Disorders (9) · Autism Spectrum Disorder (2) · Behavior (1) · Social Behavior (1)
Bumetanide (2) · Amitriptyline (1) · Fluoxetine (1) · Memantine (1) · Oxytocin (1) · Secretin (1) · balovaptan (1)
Institut de Recherches Internationales Servier (2) · Hoffmann-La Roche (1) · Massachusetts General Hospital (1) · Neuropharm (1) · Repligen Corporation (1) · Seaside Therapeutics, Inc. (1) · University of Missouri, Kansas City (1) · University of Sao Paulo General Hospital (1)
United States (6) · Brazil (3) · France (3) · Italy (3) · Spain (3) · United Kingdom (3) · Hungary (2) · Poland (2) · Portugal (2) · Australia (1) · Canada (1) · Czechia (1) · Germany (1) · Netherlands (1) · Slovakia (1)
Gagan Joshi, MD (1) · Helena P. Brentani, PHD (1) · Jessica A. Hellings, MD (1) · Paul Wang, M.D. (1)
PMID 39816573, PMID 35151410, PMID 36006807, PMID 37794745, PMID 37811711, PMID 41198718
2017 (2)